| |||
January 20, 2021 How the pandemic has changed the rules for life sciences deals COVID-19 became an unexpected M&A hurdle, as life sciences deal values have failed to reach the annual new normal of US$200 billion. An EY article provides details. | |||
|
![]() |
| |||
January 20, 2021 How the pandemic has changed the rules for life sciences deals COVID-19 became an unexpected M&A hurdle, as life sciences deal values have failed to reach the annual new normal of US$200 billion. An EY article provides details. | |||
|
| |